STRO: Accelerated ADC pipeline shows strong efficacy, safety, and innovation in dual payload strategies
Three clinical programs are advancing rapidly, with STRO-004 showing strong early efficacy and safety across multiple tumor types. Dual payload ADCs demonstrate potential to overcome resistance, supported by robust preclinical and clinical data.Based on Sutro Biopharma, Inc. [STRO] H.C. Wainwright…
Story updates
04:16:32 PM UTC
SquawkNews
STRO: Accelerated clinical progress and dual payload innovation drive promising oncology pipeline
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.